NKGen Biotech, Inc.

Graf Acquisition Corp. IV, trading under the ticker GFOR, is a blank-check company sponsored by Graf Acquisition Holdings IV, LLC, an affiliate of Graf Holdings led by James Graf. The SPAC completed its initial public offering in 2021 targeting the healthcare and life sciences sector. By mid-2022, the vehicle had announced a definitive business combination agreement with NKGen Biotech, Inc., a clinical-stage cell therapy company developing natural killer cell-based treatments for neurodegenerative diseases and oncology indications. The August 2022 10-Q filing, carrying accession number 0001410578-22-002592, reflects the company's financial position during the pending merger period. Sign up at SpacDesk for the complete filing history, deal timelines, and sponsor intelligence on GFOR and hundreds of other SPACs.